SmithKline Sells Drugs to Roche, Novartis.(SmithKline Beecham has sold rights to its Kytril antiemetic drug to Roche )(Brief Article)

SmithKline Beecham has sold rights to its Kytril antiemetic drug to Roche for $1.2 billion, and tights to the herpes treatments Famvir and Vectavir/Denavir to Novartis for $1.6 billion. The drugs …